The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis

The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis

Background: We aimed to investigate the change of hepatitis B virus (HBV) viral loads and HBV reactivation (HBVr) in rheumatoid arthritis (RA) patients after tapering the dose of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Methods: This two-center analysis retro...

Full description

Bibliographic Details
Main Authors: Der-Yuan Chen, Hsin-Hua Chen, Shih-Hsin Chang, Yi-Ming Chen, Po-Hao Huang, Chia-Wei Hsieh, Joung-Liang Lan, Kuo-Tung Tang
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Clinical Medicine
Subjects:
antirheumatic agents
biological products
hepatitis B
rheumatoid arthritis
Online Access:https://www.mdpi.com/2077-0383/12/1/86

Internet

https://www.mdpi.com/2077-0383/12/1/86

Similar Items